S-1: Aclarion Files S-1 for Resale of Up to 20 Million Shares by White Lion Capital Amid Nasdaq Compliance Concerns

Aclarion, Inc. has filed an S-1 registration statement for the resale of up to 20 million shares of its common stock by White Lion Capital, while the company addresses compliance issues with Nasdaq listing requirements.

Summary

• Aclarion has filed an S-1 registration statement for the resale of up to 20,000,000 shares of its common stock by White Lion Capital.
• The company may receive up to $7.1 million from the sale of common stock to White Lion Capital pursuant to a purchase agreement, once the registration statement is declared effective.
• Aclarion is currently not in compliance with Nasdaq's minimum bid price and stockholders' equity requirements and has appealed delisting notices.
• The company intends to implement a reverse stock split to regain compliance with Nasdaq's bid price requirement.
• Aclarion is a healthcare technology company focused on improving clinical treatments for low back and neck pain using Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers.
• The company's technology, NOCISCAN, aims to assist surgeons in determining the optimal surgical procedure for patients with lumbar spine pain.
• A clinical study showed that 97% of patients experienced clinical improvement when discs identified as painful by NOCISCAN were included in surgical treatment.
• Aclarion has secured Category III CPT codes for its technology, which is a step towards reimbursement by third-party payers.
• The company's commercialization strategy involves securing payer contracts, engaging key opinion leaders, and expanding its network of imaging centers and surgeons.
• Aclarion is also participating in a $150 million NIH-funded study to evaluate data inputs for predicting optimal treatment paths for back pain patients.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive aspects such as the technology's potential and clinical study results, the company's financial struggles, Nasdaq compliance issues, and dependence on future funding raise significant concerns.

Positives

• Aclarion has a strategic partnership with Alphatec Holdings, Inc. to co-market Nociscan in targeted markets.
• The company has an intellectual property portfolio consisting of 23 U.S. Patents, 17 Foreign Patents, 6 pending U.S. patent applications, and 7 pending Foreign patent applications.
• Aclarion's technology has been selected to participate in a $150 million NIH-funded study to evaluate data inputs for predicting optimal treatment paths for back pain patients.
• The company has secured Category III CPT codes for its technology, which is a step towards reimbursement by third-party payers.
• A clinical study showed that 97% of patients experienced clinical improvement when discs identified as painful by NOCISCAN were included in surgical treatment.

Negatives

• Aclarion is currently not in compliance with Nasdaq's minimum bid price and stockholders' equity requirements and has appealed delisting notices.
• The company has a history of net losses and expects to continue to incur losses for the foreseeable future.
• The auditors of the company's financial statements have expressed substantial doubt about its ability to continue as a going concern.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's commercial software products currently depend on compatible use with a limited number of MR scanners that are provided by one MR scanner vendor, SIEMENS.

Risks

• The company's commercial success depends on attaining significant market acceptance of its technology among patients, clinicians, and imaging facilities.
• If adequate reimbursement becomes unavailable for the procedures that use the company's diagnostic technology, it could diminish sales.
• The company's collection, use, storage, disclosure, transfer and other processing of sensitive and personal information could give rise to significant costs, liabilities and other risks.
• The company's current product is supported by a single clinical study at a single clinical center involving one spine surgeon who has a financial interest in the Company.
• The company may fail to continue to meet the listing standards of The Nasdaq Capital Market whether or not this offering occurs.

Future Outlook

The company expects expenses to increase as it invests in sales, marketing, and engineering resources and brings its products to market. The company will need to raise additional funds to continue funding its technology development and commercialization efforts.

Industry Context

The company operates in the $134.5B U.S. low back and neck pain market, which is the most costly healthcare condition in the United States. The company's technology aims to address the lack of objective, cost-effective, and noninvasive diagnostics for reliably identifying the source of a patient's pain.

Comparison to Industry Standards

• The current primary diagnostic standard is the MRI, which is useful for showing abnormal structures and tissue dehydration, but, we believe, cannot reliably identify specific discs that are causing pain.
• To diagnose specific discs that are causing pain, a needle-based Provocation Discogram test (PD Test) has been developed.
• PD Tests have been shown to be highly accurate when performed properly.
• However, a PD Test is invasive, subjective and unpleasant for the patient as the patient needs to be awake in order to tell the physician if the pain the physician is purposefully causing in the disc is the same as the pain the patient feels when they are experiencing a back pain episode.
• In addition, recent evidence has shown that the action of inserting a needle into a normal disc during a discogram procedure leads to an increased rate of degeneration in these previously normal discs.

Stakeholder Impact

• Shareholders may experience dilution due to the potential issuance of shares to White Lion Capital.
• Shareholders may experience a decline in the value of their shares if the company is delisted from Nasdaq.
• The company's ability to continue as a going concern is uncertain, which could impact stakeholders.

Next Steps

• The company intends to implement a reverse stock split to regain compliance with Nasdaq's bid price requirement.
• The company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq.
• The company is currently evaluating its available options to resolve the deficiency and regain compliance with the Stockholders Equity Requirement.

Key Dates

Keywords

Aclarion, White Lion Capital, NOCISCAN, MRS, Low Back Pain, Nasdaq, CPT Codes, Reverse Stock Split, Delisting, S-1 Filing